Evidence map›Paper›PMID 34966427›Full record

ArticleJournal of oncology2021

Low-Dose Albendazole Inhibits Epithelial-Mesenchymal Transition of Melanoma Cells by Enhancing Phosphorylated GSK-3

Zhiqiang He, Shun Lei, Fucheng Liang, Liuchang Tan, Weinan Zhang, Luoyingzi Xie, Hong Zheng, Yuangang Lu

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhiqiang HeDepartment of Plastic & Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, Chongqing 400042, China.ORCID https://orcid.org/0000-0001-8536-5970
Shun LeiDepartment of Oncology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Chongqing 400038, China.ORCID https://orcid.org/0000-0001-5802-5356
Fucheng LiangDepartment of Plastic & Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, Chongqing 400042, China.ORCID https://orcid.org/0000-0002-5222-7632
Liuchang TanDepartment of Plastic & Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, Chongqing 400042, China.ORCID https://orcid.org/0000-0002-8068-3467
Weinan ZhangDepartment of Plastic & Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, Chongqing 400042, China.ORCID https://orcid.org/0000-0001-5402-1534
Luoyingzi XieThe Institute of Immunology, Army Medical University, Chongqing 400038, China.ORCID https://orcid.org/0000-0002-2481-2690
Hong ZhengDepartment of Thoracic Surgery, Xinqiao Hospital, Amy Medical University, Chongqing 400037, China.ORCID https://orcid.org/0000-0003-3725-4541
Yuangang LuDepartment of Plastic & Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, Chongqing 400042, China.ORCID https://orcid.org/0000-0001-8042-4679
Army Medical University · CNXinqiao Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Albendazole (ABZ) is an effective broad-spectrum anthelmintic agent that has been widely used for humans and animals. Previous studies have reported that ABZ exhibits antitumor effects against melanoma and other different cancer types; however, it is unknown whether ABZ exerts the inhibitory effect against melanoma metastasis. In this study, we aimed to investigate the inhibitory effect of ABZ on melanoma cells. Through in vitro studies, we discovered that low-dose ABZ treatment significantly inhibited the migration and invasion, but not the proliferation, of A375 and B16-F10 cells in a dose-dependent manner. Further analysis revealed that ABZ treatment reduced the expression level of snail family transcriptional repressor 1 (Snail) in the cytoplasm and nucleus by decreasing the levels of phosphorylated AKT (pAKT) Ser473/GSK-3

Identifiers

PMID34966427
PMCPMC8712124
OpenAlexW4200397035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.